Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
2.740
+0.020 (0.74%)
Aug 11, 2025, 2:13 PM - Market open
Taysha Gene Therapies Stock Forecast
Stock Price Forecast
The 6 analysts that cover Taysha Gene Therapies stock have a consensus rating of "Strong Buy" and an average price target of $8.17, which forecasts a 198.18% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $11.
Price Target: $8.17 (+198.18%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 11, 2025.
Analyst Ratings
The average analyst rating for Taysha Gene Therapies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 3 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +191.97% | Jul 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +191.97% | Jul 1, 2025 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +191.97% | Jun 10, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $9 → $11 | Strong Buy | Maintains | $9 → $11 | +301.46% | Jun 3, 2025 |
| Needham | Needham | Strong Buy Reiterates $6 → $8 | Strong Buy | Reiterates | $6 → $8 | +191.97% | Jun 2, 2025 |
Financial Forecast
Revenue This Year
7.29M
from 8.33M
Decreased by -12.55%
Revenue Next Year
4.62M
from 7.29M
Decreased by -36.65%
EPS This Year
-0.34
from -0.36
EPS Next Year
-0.39
from -0.34
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.8M | 15.8M | 53.2M | ||
| Avg | 7.3M | 4.6M | 15.0M | ||
| Low | 2.3M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 89.0% | 116.1% | 1,053.3% | ||
| Avg | -12.6% | -36.7% | 225.3% | ||
| Low | -73.0% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.30 | -0.33 | -0.28 | ||
| Avg | -0.34 | -0.39 | -0.36 | ||
| Low | -0.37 | -0.54 | -0.42 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.